What is the appropriate dosing regimen of Testopel (testosterone pellets) for a trans‑male patient?

Testopel Dosing for Transgender Males

For transgender males, Testopel should be dosed at 675-900 mg (9-12 pellets of 75 mg each) subcutaneously every 3-4 months, with dose titration based on testosterone levels measured 1 month after insertion. 1, 2

Initial Dosing Strategy

The FDA-approved Testopel label recommends 150-450 mg every 3-6 months for androgen-deficient males 1, but this dosing is insufficient for transgender males in clinical practice. Real-world evidence demonstrates that:

• Start with 9-12 pellets (675-900 mg) at initial insertion 2, 3
• Among sexual medicine specialists, 80.5% implant at least 10 pellets at initiation, with only 3.4% using fewer than 6 pellets 3
• The manufacturer's recommendation of 2-6 pellets is inadequate for achieving therapeutic testosterone levels in transgender patients 3

Monitoring and Dose Adjustment

Measure testosterone levels at 1 month post-insertion 4, 2:

• Target mid-normal male range: 300-800 ng/dL (ideally 500-600 ng/dL)
• Testosterone peaks at 1 month and remains therapeutic for approximately 4 months 2, 5
• Adjust the number of pellets and/or dosing interval to maintain levels in normal range 4

Re-implantation timing:

• Most commonly every 3-4 months 2, 3
• Can extend to 6 months if testosterone levels remain adequate 1, 5
• Measure testosterone at the end of the dosing interval to determine timing 4

Dose Titration Considerations

After initial insertion, 41-60% of patients remain on their starting dose without adjustment 3, indicating that proper initial dosing is critical. When adjustments are needed:

• If testosterone >700 ng/dL: reduce number of pellets
• If testosterone <300 ng/dL: increase number of pellets or shorten interval 4
• Higher pellet numbers (10-12) provide more consistent therapeutic levels 5

Critical Safety Monitoring

Polycythemia is the most significant concern with testosterone pellets in transgender males:

• Hematocrit elevation occurs in 46.67% of patients 2 - substantially higher than other testosterone formulations
• Check hematocrit at baseline, 3-6 months, then annually 4
• If hematocrit >54%, stop therapy until it decreases; evaluate for hypoxia/sleep apnea; reinitiate at reduced dose 4
• This high polycythemia rate warrants caution in patients with history of erythrocytosis or thromboembolic risk 2

Additional Monitoring Parameters

At each visit, assess for:

• Signs of infection, fibrosis, or pellet extrusion at insertion site 4
• Pellet extrusion occurs in 13.33% of patients 2
• Hematoma (6.67%) and cellulitis (3.33%) are less common 2

Efficacy markers in transgender males:

• 100% achieve amenorrhea and voice deepening 2
• 96.3% experience increased androgen-dependent hair growth 2
• 70% report improved libido 2

Clinical Pearls

The pharmacokinetics in transgender males mirror those in cisgender hypogonadal men 2, allowing application of general testosterone pellet principles. However, the substantially elevated polycythemia risk in transgender males requires heightened vigilance compared to standard hypogonadism treatment.

Patient satisfaction is high (56-90% satisfied "most times" to "almost always") 3, making pellets a reasonable alternative when patients desire long-acting formulation without frequent injections or daily topical applications.